Contemporary Antiplatelet Pharmacotherapy in the Management of Acute Coronary Syndromes
Daniel R Mangels1, Ashwin Nathan1, Sony Tuteja1
1Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA.
Insights
For acute coronary syndrome (ACS), clopidogrel and ticagrelor are recommended P2Y12 antagonists for pretreatment. Newer therapies show promise but increase bleeding risks, requiring careful consideration in high-risk patients.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Antiplatelet therapies are crucial for managing acute coronary syndrome (ACS).
- The role of P2Y12 antagonists as pretreatment before catheterization is debated, especially in patients with high bleeding risk.
Purpose of the Study:
- To review current literature on antiplatelet therapy for ACS pretreatment and treatment.
- To evaluate contemporary and novel antiplatelet agents in ACS management.
Main Methods:
- Literature review of contemporary and novel antiplatelet therapies.
- Analysis of evidence for P2Y12 antagonists and glycoprotein IIa/IIIb antagonists in ACS.
Main Results:
- P2Y12 antagonists significantly reduce morbidity and mortality in ACS.
- Clopidogrel and ticagrelor have sufficient evidence for ACS pretreatment.
- Prasugrel is supported for patients undergoing percutaneous intervention (PCI).
- Glycoprotein IIa/IIIb antagonists are optimal adjuvant therapy for high-risk ACS during/after PCI.
- Newer agents like protease-activated receptor 1 antagonists are promising but increase bleeding risk.
Conclusions:
- Clopidogrel and ticagrelor are the only P2Y12 antagonists with sufficient evidence for ACS pretreatment.
- Glycoprotein IIa/IIIb antagonists are valuable for high-risk ACS patients.
- Novel antiplatelet therapies require further evaluation due to increased bleeding risks.
Purpose Of Review:
Antiplatelet therapies are pivotal treatments in the management of acute coronary syndrome (ACS) with or without revascularization. In recent years, the use of P2Y12 antagonists prior to catheterization, so-called pretreatment, has been questioned, particularly in patients who may be at higher bleeding risks. The purpose of this review was to evaluate the current literature on contemporary and novel antiplatelet therapy in the pretreatment and treatment of ACS.
Recent Findings:
The P2Y12 receptor antagonists are associated with substantial reductions in morbidity and mortality for all types of ACS but only clopidogrel and ticagrelor have sufficient evidence for use in the pretreatment setting. The data regarding prasugrel support the use in patients undergoing percutaneous intervention (PCI). The glycoprotein IIa/IIIb antagonists are the most optimal for use in high-risk ACS as an adjuvant therapy during and after PCI. In summary, although all P2Y12 antagonists have morbidity- and mortality-reducing effects in ACS, only clopidogrel and ticagrelor have sufficient evidence in the pretreatment setting. Newer antiplatelet therapies, most notably the protease-activated receptor 1 antagonists, are evolving and promising but are associated with greater bleeding risks.
Related Concept Videos
01:26Acute Coronary Syndrome V: Nursing Management
01:30Acute Coronary Syndrome I: Introduction
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:15Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...